## Supplementary material

# Inflammatory plasma proteins predict short-term mortality in patients with an acute myocardial infarction 

Schmitz T, Harmel E, Heier M, Peters A, Linseisen J, Meisinger C

## Protein Measurement

Proteins were measured by Olink Proteomics (Uppsala, Sweden). Protein concentrations of plasma samples were determined using the Pro-seekQ3XXMultiplex Inflammation Panel based on the proximity extension assay (PEA). Further information can be found on the website. The measurement method can be described as follows: This assay uses a pair of specific antibodies labeled with oligonucleotides that target each protein. When two matching oligonucleotides are close to each other, a new protein-specific sequence is formed by proximity-dependent DNA polymerization. The amount of each protein-specific sequence is then quantified by real-time quantitative polymerase chain reaction (qPCR). This method can be used to simultaneously quantify 92 proteins in 96 samples at the same time. Protein concentrations are reported as Normalized Protein Expression (NPX) values, a relative unit used by Olink. It is calculated from $C t$ values (qPCR) and is on a $\log 2$ scale. A difference of 1 NPX corresponds to a doubling of protein concentration. Normalization is performed to minimize variation within and between assays. The limit of detection (LOD) is calculated separately for each Olink assay and sample plate.

## GFRACE Score calculation

Since we did not possess all information that was necessary to exactly replicate the GRACE score, we used all data that was available in order to replicate the GRACE score as best as possible. In the following, we explain the calculation that was used for the score we used. It was strongly orientated on the calculations methods describe in this document [1].

Variable 1: Age: This variable was replicated exactly using the following assignments:

```
Age (years) Number of points
<35 0
```

| $35-45$ | $($ Age-35 $) *(1.8)$ |
| :--- | :--- |
| $45-55$ | $18+($ Age-45 $) *(1.8)$ |
| $55-65$ | $36+($ Age-55)*(1.8) |
| $65-75$ | $54+($ Age-65)*(1.9) |
| $75-85$ | $73+($ Age-75)*(1.8) |
| $85-90$ | $91+($ Age-85)* $(1.8)$ |
| $\geq 90$ | 100 |

Variable 2: Heart rate: This variable was also exactly replicated using the following assignments:

Variable 3: systolic blood pressure: This variable was replicated exactly as well. The following assignments were used:

| sBP $(\mathrm{mmHg})$ | Number of points |
| :--- | :--- |
| $<80$ | 58 |
| $80-100$ | $58-(\mathrm{sBP}-80)^{*}(10 / 20)$ |
| $100-110$ | $48-(\mathrm{sBP}-100)^{*}(5 / 10)$ |
| $110-120$ | $43-(\mathrm{sBP}-110)^{*}(4 / 10)$ |
| $120-130$ | $39-(\mathrm{sBP}-120)^{*}(5 / 10)$ |
| $130-140$ | $34-(\mathrm{sBP}-130)^{*}(5 / 10)$ |
| $140-150$ | $29-(\mathrm{sBP}-140)^{*}(5 / 10)$ |
| $150-160$ | $24-(\mathrm{sBP}-150)^{*}(5 / 10)$ |
| $160-180$ | $19-(\mathrm{sBP}-160)^{*}(9 / 20)$ |
| $180-200$ | $10-(\mathrm{sBP}-180)^{*}(10 / 20)$ |
| $\geq 200$ | 0 |

Variable 4: Creatinine: Once more, this variable was replicated exactly according to the following table:

## Creatinine mg/dL Number of points

| <0.2 | (Creatinine-0)*(1/0.2) |
| :---: | :---: |
| 0.2-0.4 | $1+(\text { Creatinine }-0.2)^{*}(2 / 0.2)$ |
| 0.4-0.6 | $3+(\text { Creatinine }-0.4)^{*}(1 / 0.2)$ |
| 0.6-0.8 | $4+\left(\right.$ Creatinine-0.6)* $\left.{ }^{*} / 2 / 0.2\right)$ |
| 0.8-1.0 | $6+($ Creatinine -0.8$) *(1 / 0.2)$ |
| 1.0-1.2 | 7 + (Creatinine-1.0)* $(1 / 0.2)$ |
| 1.2-1.4 | $8+($ Creatinine-1.2)* $(2 / 0.2)$ |
| 1.4-1.6 | $10+($ Creatinine-1.4)*(1/0.2) |
| 1.6-1.8 | $11+($ Creatinine-1.6)* $(2 / 0.2)$ |
| 1.8-2.0 | $13+($ Creatinine-1.8)* $(1 / 0.2)$ |
| 2.0-3.0 | $14+\left(\right.$ Creatinine-2.0)* $\left.{ }^{*} / 1\right)$ |
| 3.0-4.0 | $21+\left(\right.$ Creatinine-3.0)* ${ }^{*}(7 / 1)$ |
| $\geq 4.0$ | 28 |

Variable 5: Killip class: We did not have the exact information used for this classification. It classifies symptoms of acute heart failure after AMI using 4 categories. We only possessed data on left ventricular ejection fraction (LVEF), which does not assess heart failure from a symptom-oriented perspective but rather a heart function oriented perspective. Nevertheless, both are legitimate methods to assess heart function and heart failure and are supposedly highly correlated. We used the following table for assignment:

| Killip Class | LVEF | Number of points |
| :--- | :--- | :--- |
| I class | Normal (>50\%) | 0 |
| II class | Mildly reduced (41-50\%) | 20 |
| III class | Moderately reduced (31-40\%) | 39 |
| IV class | Strongly reduced $(\leq 30 \%)$ | 59 |

Variable 6: ST deviation: As our sample consisted of only AMI events that were classified as ST-elevation myocardial infarctions, this variable was set 1 for each case.

Variable 7: Elevated cardiac enzymes: We used measured levels of Troponin I to calculate this variable. Troponin T was barely measured and CK-MB levels were very incomplete. Troponin I on the other hand was available for the vast majority of cases. We used the cut off values of the laboratory that performed the measurement (high-sensitive Troponin I, reference: 0-14 $\mathrm{pg} / \mathrm{ml}$ )

| Troponin I value | Assignment |
| :--- | :--- |
| $0-14 \mathrm{pg} / \mathrm{ml}$ | 0 |
| $>14 \mathrm{pg} / \mathrm{ml}$ | 1 |

Variable 8: Cardiac arrest at presentation: This information was not exactly recorded by the registry. Nevertheless, there is a variable with information on prehospital cardiac arrest (yes/no). As both definitions are not exactly equivalent but very closely resemble each other, we used this variable for the score.

| Prehospital cardiac arrest | Assignment |
| :--- | :--- |
| no | 0 |
| yes | 1 |

The final score was then calculated using the following formula:
GRACE score $=$ Age + Heart rate + systolic blood pressure + Creatinine $+(28$ *ST deviation $)+$ LVEF + (14 * elevated cardiac enzymes) + (39 * prehospital cardiac arrest)

Table S1: Results of the logistic regression models including the biomarkers full names

| Biomarker |  | logistic regression |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | adjusted for sex and age |  |  | multivariable adjusted |  |  |
| Short name | Full name | Odds ratio | FDR-adjusted $p$-value | - $\log _{10} p$-value <br> (FDR adjusted) | Odds ratio | FDR-adjusted p-value | $-\log _{10} p$-value (FDR adjusted) |
| ADA | Adenosine Deaminase (ADA) | 1,459251 | 2,07E-02 | 1,683661 | 1,367166 | 1,22E-01 | 0,913469 |
| ARTN | Artemin (ARTN) | 1,019437 | 9,32E-01 | 0,030549 | 1,025778 | 9,35E-01 | 0,029182 |
| AXIN1 | Axin-1 (AXIN1) | 1,206477 | 4,09E-01 | 0,387762 | 1,127364 | 6,99E-01 | 0,155648 |
| Beta-NGF | Beta-nerve growth factor (Beta-NGF) | 1,214458 | 2,76E-01 | 0,559639 | 1,199736 | 4,64E-01 | 0,333048 |
| CASP-8 | Caspase-8 (CASP-8) | 1,527136 | 1,16E-02 | 1,936573 | 1,438416 | 8,42E-02 | 1,074817 |
| CCL19 | C-C motif chemokine 19 (CCL19) | 1,338905 | 2,23E-01 | 0,650865 | 1,256334 | 4,64E-01 | 0,333048 |
| CCL20 | C-C motif chemokine 20 (CCL20) | 1,792795 | 1,74E-03 | 2,759372 | 1,67585 | 1,77E-02 | 1,751456 |
| CCL23 | C-C motif chemokine 23 (CCL23) | 1,368019 | 2,42E-01 | 0,615585 | 1,201766 | 5,91E-01 | 0,228623 |
| CCL25 | C-C motif chemokine 25 (CCL25) | 1,803536 | 2,07E-02 | 1,683661 | 1,596185 | 1,22E-01 | 0,913469 |
| CCL28 | C-C motif chemokine 28 (CCL28) | 0,853616 | 5,50E-01 | 0,259853 | 0,896117 | 7,46E-01 | 0,127159 |
| CCL3 | C-C motif chemokine 3 (CCL3) | 1,773569 | 1,09E-02 | 1,962339 | 1,632462 | 8,12E-02 | 1,090194 |
| CCL4 | C-C motif chemokine 4 (CCL4 ) | 1,725633 | 1,71E-02 | 1,767309 | 1,570443 | 1,00E-01 | 0,9981 |
| CD40 | CD40L receptor (CD40) | 1,848334 | 6,86E-03 | 2,163473 | 1,751388 | 1,00E-01 | 0,9981 |
| CDCP1 | CUB domain-containing protein 1 (CDCP1) | 1,236527 | 4,20E-01 | 0,377 | 1,108009 | 7,76E-01 | 0,109889 |
| CXCL1 | C-X-C motif chemokine 1 (CXCL1) | 1,49951 | 7,18E-02 | 1,143865 | 1,29955 | 4,22E-01 | 0,374333 |
| CXCL10 | C-X-C motif chemokine 10 (CXCL10) | 1,230773 | 3,87E-01 | 0,412713 | 1,14053 | 6,73E-01 | 0,171949 |
| CXCL11 | C-X-C motif chemokine 11 (CXCL11) | 1,220989 | 4,09E-01 | 0,387762 | 1,145101 | 6,73E-01 | 0,171949 |
| CXCL5 | C-X-C motif chemokine 5 (CXCL5 ) | 0,814449 | 4,09E-01 | 0,387762 | 0,715062 | 3,14E-01 | 0,502609 |
| CXCL6 | C-X-C motif chemokine 6 (CXCL6) | 1,350406 | 2,28E-01 | 0,642838 | 1,192415 | 5,91E-01 | 0,228623 |
| CXCL9 | C-X-C motif chemokine 9 (CXCL9 ) | 1,355352 | 2,90E-01 | 0,537769 | 1,40661 | 3,64E-01 | 0,438826 |


| CST5 | Cystatin D (CST5) | 2,228241 | 1,36E-04 | 3,867657 | 2,256201 | 2,29E-03 | 2,639662 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| DNER | Delta and Notch-like epidermal growth factor-related receptor (DNER) | 0,713556 | 1,83E-01 | 0,737731 | 0,749729 | 3,89E-01 | 0,41057 |
| CCL11 | Eotaxin (CCL11) | 1,361724 | 2,70E-01 | 0,5689 | 1,230812 | 5,63E-01 | 0,249667 |
| 4E-BP1 | Eukaryotic translation initiation factor 4Ebinding protein 1 (4E-BP1) | 2,068244 | 2,38E-04 | 3,62331 | 1,929884 | 5,24E-03 | 2,280795 |
| FGF-19 | Fibroblast growth factor 19 (FGF-19) | 1,056356 | 8,39E-01 | 0,076467 | 0,985287 | 9,65E-01 | 0,015653 |
| FGF-21 | Fibroblast growth factor 21 (FGF-21) | 2,347462 | 1,67E-04 | 3,777974 | 2,32973 | 2,29E-03 | 2,639662 |
| FGF-23 | Fibroblast growth factor 23 (FGF-23) | 1,839416 | 3,81E-04 | 3,419399 | 1,785977 | 5,26E-03 | 2,278908 |
| FGF-5 | Fibroblast growth factor 5 (FGF-5) | 1,141635 | 6,15E-01 | 0,211407 | 1,156641 | 6,55E-01 | 0,183431 |
| FIt3L | Fms-related tyrosine kinase 3 ligand (FIt3L) | 1,571952 | 6,90E-02 | 1,161172 | 1,390507 | 2,99E-01 | 0,524226 |
| CX3CL1 | Fractalkine (CX3CL1 ) | 1,658313 | 3,16E-02 | 1,500252 | 1,489904 | 2,28E-01 | 0,641582 |
| GDNF | Glial cell line-derived neurotrophic factor (GDNF) | 0,862239 | 5,85E-01 | 0,232905 | 0,844975 | 5,91E-01 | 0,228623 |
| HGF | Hepatocyte growth factor (HGF) | 0,877516 | 6,12E-01 | 0,213553 | 0,915559 | 7,76E-01 | 0,109889 |
| IFN-gamma | Interferon gamma (IFN-gamma) | 0,948447 | 8,39E-01 | 0,076022 | 0,952337 | 9,06E-01 | 0,043016 |
| IL-1 alpha | Interleukin-1 alpha (IL-1 alpha) | 0,846514 | 4,55E-01 | 0,341927 | 0,812555 | 4,64E-01 | 0,333048 |
| IL10 | Interleukin-10 (IL10) | 2,263612 | 6,17E-05 | 4,209401 | 2,112065 | 2,29E-03 | 2,639662 |
| IL-10RA | Interleukin-10 receptor subunit alpha (IL10RA) | 0,931748 | 8,26E-01 | 0,082857 | 0,965092 | 9,23E-01 | 0,03479 |
| IL-10RB | Interleukin-10 receptor subunit beta (IL10RB) | 1,023719 | 9,30E-01 | 0,031496 | 0,860805 | 6,86E-01 | 0,163851 |
| IL-12B | Interleukin-12 subunit beta (IL-12B) | 1,117992 | 7,34E-01 | 0,134034 | 0,955389 | 9,13E-01 | 0,039467 |
| IL13 | Interleukin-13 (IL-13) | 0,729088 | 4,09E-01 | 0,387762 | 0,742661 | 5,63E-01 | 0,249667 |
| IL-15RA | Interleukin-15 receptor subunit alpha (IL15RA) | 1,188786 | 5,01E-01 | 0,300297 | 1,040352 | 9,13E-01 | 0,039467 |
| IL-17A | Interleukin-17A (IL-17A) | 1,269216 | 2,76E-01 | 0,559639 | 1,216924 | 5,10E-01 | 0,292328 |
| IL-17C | Interleukin-17C (IL-17C) | 1,255062 | 3,16E-01 | 0,500753 | 1,15192 | 6,68E-01 | 0,175121 |
| IL18 | Interleukin-18 (IL-18) | 1,464012 | 8,98E-02 | 1,046568 | 1,309418 | 3,89E-01 | 0,41057 |
| IL-18R1 | Interleukin-18 receptor 1 (IL-18R1) | 1,389716 | 2,23E-01 | 0,650865 | 1,231369 | 5,53E-01 | 0,257392 |
| IL2 | Interleukin-2 (IL-2) | 0,768338 | 5,03E-01 | 0,298111 | 0,716867 | 5,38E-01 | 0,269308 |


| IL-2RB | Interleukin-2 receptor subunit beta (IL-2RB) | 0,969165 | 9,30E-01 | 0,031639 | 0,994825 | 9,83E-01 | 0,007363 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| IL-20 | Interleukin-20 (IL-20) | 1,406961 | 3,68E-02 | 1,433883 | 1,307969 | 2,28E-01 | 0,641582 |
| IL-20RA | Interleukin-20 receptor subunit alpha (IL20RA) | 0,759512 | 3,16E-01 | 0,500753 | 0,746094 | 3,89E-01 | 0,41057 |
| IL-22 RA1 | Interleukin-22 receptor subunit alpha-1 (IL22 RA1) | 1,207612 | 3,74E-01 | 0,427384 | 1,147703 | 6,29E-01 | 0,201449 |
| IL-24 | Interleukin-24 (IL-24) | 1,241509 | 3,16E-01 | 0,500753 | 1,164791 | 5,91E-01 | 0,228623 |
| IL33 | Interleukin-33 (IL-33) | 1,531246 | 3,16E-02 | 1,500252 | 1,327011 | 3,01E-01 | 0,52198 |
| IL4 | Interleukin-4 (IL-4) | 0,935829 | 8,39E-01 | 0,076467 | 0,987987 | 9,67E-01 | 0,014551 |
| IL5 | Interleukin-5 (IL5) | 0,928566 | 8,39E-01 | 0,076467 | 0,88322 | 7,76E-01 | 0,109889 |
| IL6 | Interleukin-6 (IL6) | 2,294701 | 6,17E-05 | 4,209401 | 2,071556 | 2,29E-03 | 2,639662 |
| IL7 | Interleukin-7 (IL-7) | 0,99966 | 9,99E-01 | 0,000606 | 0,911993 | 7,88E-01 | 0,103733 |
| IL8 | Interleukin-8 (IL-8) | 2,070095 | 1,52E-04 | 3,818846 | 1,914758 | 4,39E-03 | 2,357868 |
| LAP TGF-beta-1 | Latency-associated peptide transforming growth factor beta-1 (LAP TGF-beta-1) | 1,625984 | 4,54E-02 | 1,342763 | 1,44742 | 2,39E-01 | 0,620782 |
| LIF | Leukemia inhibitory factor (LIF) | 1,586017 | 1,36E-02 | 1,866801 | 1,410367 | 1,22E-01 | 0,913469 |
| LIF-R | Leukemia inhibitory factor receptor (LIF-R) | 1,840224 | 4,65E-03 | 2,332921 | 1,689383 | 5,69E-02 | 1,244526 |
| CSF-1 | Macrophage colony-stimulating factor 1 (CSF-1) | 0,970718 | 9,30E-01 | 0,031639 | 0,837662 | 5,41E-01 | 0,266422 |
| MMP-1 | Matrix metalloproteinase-1 (MMP-1) | 1,27647 | 3,85E-01 | 0,414744 | 1,228755 | 5,63E-01 | 0,249667 |
| MMP-10 | Matrix metalloproteinase-10 (MMP-10) | 1,305006 | 2,89E-01 | 0,538736 | 1,229525 | 5,53E-01 | 0,257392 |
| MCP-1 | Monocyte chemotactic protein 1 (MCP-1) | 2,261392 | 1,52E-04 | 3,818846 | 2,017032 | 5,14E-03 | 2,28895 |
| MCP-2 | Monocyte chemotactic protein 2 (MCP-2) | 1,256696 | 3,74E-01 | 0,427384 | 1,124069 | 7,19E-01 | 0,143478 |
| MCP-3 | Monocyte chemotactic protein 3 (MCP-3) | 1,386214 | 1,50E-01 | 0,824682 | 1,197157 | 5,63E-01 | 0,249667 |
| MCP-4 | Monocyte chemotactic protein 4 (MCP-4) | 1,104003 | 7,43E-01 | 0,129232 | 1,04253 | 9,13E-01 | 0,039467 |
| CD244 | Natural killer cell receptor 2B4 (CD244) | 1,086521 | 7,69E-01 | 0,11412 | 0,962333 | 9,13E-01 | 0,039467 |
| NT-3 | Neurotrophin-3 (NT-3) | 1,402828 | 9,60E-02 | 1,017557 | 1,379814 | 2,08E-01 | 0,682626 |
| NRTN | Neurturin (NRTN) | 1,056685 | 8,39E-01 | 0,076467 | 1,148803 | 6,73E-01 | 0,171949 |
| OSM | Oncostatin-M (OSM) | 1,334198 | 2,70E-01 | 0,5689 | 1,122343 | 7,30E-01 | 0,136583 |
| OPG | Osteoprotegerin (OPG) | 1,962426 | 4,65E-03 | 2,332921 | 1,755116 | 5,10E-02 | 1,292367 |
| PD-L1 | Programmed cell death 1 ligand 1 (PD-L1) | 1,471636 | 9,02E-02 | 1,044893 | 1,310915 | 4,22E-01 | 0,374333 |


| EN-RAGE | Protein S100-A12 (EN-RAGE ) | 1,417652 | 1,78E-01 | 0,750169 | 1,309498 | 4,27E-01 | 0,369608 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| SLAMF1 | Signaling lymphocytic activation molecule (SLAMF1) | 1,35647 | 1,73E-01 | 0,761165 | 1,250618 | 4,64E-01 | 0,333048 |
| SIRT2 | SIR2-like protein 2 (SIRT2) | 1,649695 | 3,46E-03 | 2,461013 | 1,627524 | 1,35E-02 | 1,869961 |
| STAMBP | STAM-binding protein (STAMPB) | 1,642745 | 2,96E-03 | 2,529101 | 1,616169 | 1,35E-02 | 1,869961 |
| SCF | Stem cell factor (SCF) | 0,783516 | 3,08E-01 | 0,511717 | 0,702907 | 2,39E-01 | 0,620782 |
| ST1A1 | Sulfotransferase 1A1 (ST1A1) | 2,100051 | 1,52E-04 | 3,818846 | 1,862464 | 5,24E-03 | 2,280795 |
| CD6 | T cell surface glycoprotein CD6 isoform (CD6) | 1,096301 | 7,43E-01 | 0,129232 | 1,062393 | 8,55E-01 | 0,068117 |
| CD5 | T-cell surface glycoprotein CD5 (CD5) | 1,269171 | 2,75E-01 | 0,560071 | 1,16484 | 5,91E-01 | 0,228623 |
| CD8A | T-cell surface glycoprotein CD8 alpha chain (CD8A) | 0,675613 | 9,30E-02 | 1,031571 | 0,653944 | 1,04E-01 | 0,983625 |
| TSLP | Thymic stromal lymphopoietin (TSLP) | 0,974498 | 9,30E-01 | 0,031496 | 0,903024 | 7,76E-01 | 0,109889 |
| TNFB | TNF-beta (TNFB) | 0,913816 | 7,66E-01 | 0,115758 | 0,927964 | 8,15E-01 | 0,089008 |
| TRANCE | TNF-related activation-induced cytokine (TRANCE) | 0,763408 | 2,76E-01 | 0,559639 | 0,819825 | 5,41E-01 | 0,266422 |
| TRAIL | TNF-related apoptosis-inducing ligand (TRAIL) | 1,309788 | 3,46E-01 | 0,461534 | 1,273642 | 4,64E-01 | 0,333048 |
| TGF-alpha | Transforming growth factor alpha (TGFalpha) | 1,24022 | 3,85E-01 | 0,414744 | 1,022362 | 9,44E-01 | 0,024976 |
| TWEAK | Tumor necrosis factor (Ligand) superfamily, member 12 (TWEAK) | 0,693014 | 1,50E-01 | 0,824682 | 0,772254 | 4,37E-01 | 0,359409 |
| TNF | Tumor necrosis factor (TNF) | 1,549256 | 2,52E-02 | 1,598092 | 1,51438 | 1,00E-01 | 0,9981 |
| TNFSF14 | Tumor necrosis factor ligand superfamily member 14 (TNFSF14) | 1,086963 | 7,76E-01 | 0,110318 | 0,947017 | 9,01E-01 | 0,04531 |
| TNFRSF9 | Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) | 1,806539 | 2,81E-03 | 2,551726 | 1,755729 | 2,02E-02 | 1,694853 |
| uPA | Urokinase-type plasminogen activator (uPA) | 1,327081 | 2,24E-01 | 0,649408 | 1,213091 | 5,30E-01 | 0,275721 |
| VEGFA | Vascular endothelial growth factor A (VEGFA) | 1,613109 | 3,68E-02 | 1,433883 | 1,400372 | 3,14E-01 | 0,502609 |

Table S2: Predictive ability of the individual components of the GRACE score. For each component, a ROC analyses for 28-day mortality was calculated and its results are displayed in the table below.

| Component | AUC [95\% CI] | $\boldsymbol{p - v a l u e *}$ | comment |
| :--- | :--- | :--- | :--- |
| Age | 0.6365 <br> $(0.5278-0.7497)$ | 0.0351 | AUC is calculated for the continuous variable and not the <br> categorized variable used in the GRACE score |
| Heart rate at admission | 0.5049 <br> $(0.3725-0.6336)$ | $<0.001$ | AUC is calculated for the continuous variable and not the <br> categorized variable used in the GRACE score |
| Systolic blood pressure <br> at admission | 0.7174 <br> $(0.6131-0.8131)$ | 0.1689 | AUC is calculated for the continuous variable and not the <br> categorized variable used in the GRACE score |
| Creatinine levels at <br> admission | 0.7136 <br> $(0.6024-0.8106)$ | - | - |
| ST deviation | AUC is calculated for the continuous variable and not the <br> categorized variable used in the GRACE score |  |  |
| (Elevated) cardiac <br> enzymes | $(0.5615-0.6385)$ | Not applicable, as the study cohort consisted exclusively <br> of STEMI patients |  |
| Cardiac arrest at <br> presentation | 0.6036 <br> $(0.5189-0.6941)$ | 0.0013 | AUC is calculated for the continuous variable and not the <br> categorized variable used in the GRACE score |
| Left ventricular ejection <br> fraction | 0.6134 <br> to a limited extent. However, values are displayed for the <br> sake of completeness. |  |  |

* in comparison to the biomarker score using bootstrapping

Inflammatory parameters and 28-day mortality
Multivariable adjusted


Figure S1: Multivariable adjusted logistic regression models including the additional covariate 'prehospital time'. P-values were FDR-adjusted. Names of the markers are presented for all markers with FDR-adjusted p-values below 0.05.

## Inflammatory biomarkers and 28-day mortality

Multivariable adjusted - including all cases with PCI treatment


Figure S2: Multivariable adjusted logistic regression models including only observations of patients who received PCI treatment. P-values were FDRadjusted. Names of the markers are presented for all markers with FDR-adjusted p-values below 0.05.


Figure S3: ROC curves for the biomarker score (on the left) and the combined total score (on the right) in comparison to the GRACE score (blue curve). Only cases of patients who received PCI treatment were included. The displayed p-values were obtained from comparing the AUC values via bootstrapping.

AUC values: Biomarker score: 0.7562 [95\% CI: 0.6286-0.8701]; Grace score: 0.7226 [95\% CI: 0.5853-0.8522], Total score: 0.7943 [95\% CI: $0.6456-$ 0.9231]

## REFERENCES

1 Fred Anderson, PhD, Gordon FitzGerald. Methods and formulas used to calculate the GRACE Risk Scores for patients presenting to hospital with an acute coronary syndrome: Updated 2014. Available at: https://www.outcomes-
umassmed.org/grace/files/GRACE_RiskModel_Coefficients.pdf.

